Predict your next investment

Investment Bank
FINANCE | Investment Banking
outcomecapital.com

See what CB Insights has to offer

Investments

21

Portfolio Exits

9

Funds

2

Partners & Customers

4

About Outcome Capital

Outcome Capital is a specialized investment bank with a global reach, providing middle-market growth companies in the technology and life sciences markets with a value-added client-centric approach to mergers & acquisitions, corporate finance and advisory services.

Outcome Capital Headquarter Location

11921 Freedom Dr. Suite 730

Reston, Virginia, 20190,

United States

617-431-4886

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Outcome Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Outcome Capital Rank

Latest Outcome Capital News

Outcome Capital Advises ELIOS Vision on Growth Financing Round

May 24, 2022

May 24, 2022 08:30 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )--Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved for use in Europe for adults with glaucoma, with or without cataract, and is currently undergoing clinical trials in the U.S. under an investigational device exemption (IDE). Extensive clinical data on the ELIOS procedure has been published in 12 clinical studies with over 550 eyes treated showing an IOP reduction of 20-40% from baseline. Mr. Elliot Friedman, CEO of ELIOS Vision commented; “over the past decade minimally invasive glaucoma surgeries (MIGS) have transformed the treatment of mild to moderate glaucoma but, despite the growing popularity of combining cataract and glaucoma surgery, it is not yet the preferred choice by most surgeons. We believe that the ELIOS procedure will be widely adopted due to its safety, efficacy and rapid learning curve. Outcome Capital’s strategic guidance was instrumental in closing this financing.” “Targeting the >$2.5BN glaucoma treatment market, ELIOS is positioned to disrupt the existing standard of care within the MIGS sector. As the leading cause of irreversible blindness in adults over 60, and encompassing >50 million glaucoma sufferers worldwide, ELIOS’ novel approach to interventional glaucoma management provides an exciting new option to surgeon and patients,” said Dr. Oded Ben-Joseph, Managing Director at Outcome Capital. About ELIOS Vision ELIOS Vision, Inc.( www.eliosvision.com ) is a privately held company, working to preserve sight by developing a safe and effective breakthrough solution for the millions of patients who have glaucoma. The ELIOS technology has a CE mark and has been used extensively in Europe with thousands of patients treated. In the United States, the technology is investigational and undergoing an IDE pivotal trial. About Outcome Capital Outcome Capital ( www.outcomecapital.com ) is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside. Contacts

Outcome Capital Investments

21 Investments

Outcome Capital has made 21 investments. Their latest investment was in Domain Holdings Group as part of their Series A on July 7, 2011.

CBI Logo

Outcome Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/19/2011

Series A

Domain Holdings Group

$2.9M

Yes

Matias De Tezanos, Undisclosed Angel Investors, and Valhalla Partners

1

6/16/2011

Series A

Performline

Yes

2/5/2009

Series B

Social Solutions

$6.5M

No

9/18/2008

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

4/22/2008

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/19/2011

6/16/2011

2/5/2009

9/18/2008

4/22/2008

Round

Series A

Series A

Series B

Unattributed VC

Series A

Company

Domain Holdings Group

Performline

Social Solutions

Subscribe to see more

Subscribe to see more

Amount

$2.9M

$6.5M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Matias De Tezanos, Undisclosed Angel Investors, and Valhalla Partners

Sources

1

0

0

Outcome Capital Portfolio Exits

9 Portfolio Exits

Outcome Capital has 9 portfolio exits. Their latest portfolio exit was Genesis Financial Solutions on February 10, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/10/2021

Acquired

2

2/21/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/20/2015

Acquired

Subscribe to see more

Subscribe to see more

10

3/27/2015

Acquired

Subscribe to see more

Subscribe to see more

10

7/8/2014

Acq - Fin

Subscribe to see more

Subscribe to see more

10

Date

2/10/2021

2/21/2017

5/20/2015

3/27/2015

7/8/2014

Exit

Acquired

Acquired

Acquired

Acquired

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Outcome Capital Acquisitions

1 Acquisition

Outcome Capital acquired 1 company. Their latest acquisition was Phoenix Check Cashing on March 17, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/17/2008

Debt

$99M

$0.25M

Acquired

Date

3/17/2008

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$0.25M

Note

Acquired

Sources

Outcome Capital Fund History

2 Fund Histories

Outcome Capital has 2 funds, including WWC Capital Fund II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2005

WWC Capital Fund II LP

Expansions & Growth

Closed

$60M

1

12/31/2000

WWC Capital Fund I LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2005

12/31/2000

Fund

WWC Capital Fund II LP

WWC Capital Fund I LP

Fund Type

Expansions & Growth

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$60M

$99M

Sources

1

10

Outcome Capital Partners & Customers

4 Partners and customers

Outcome Capital has 4 strategic partners and customers. Outcome Capital recently partnered with Innara Health on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/6/2022

Licensor

United States

Outcome Capital Announces Innara Health and Cardinal Health Partner to Advance Neonatal Development - Outcome Capital

Innara Health 's visibility and the pathway to the NTrainer System redesign gained momentum in 2020 after being selected to participate in the MedTech Innovator accelerator pediatric cohort .

1

1/26/2021

Client

United States

Subscribe to see more

Subscribe to see more

10

6/4/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/21/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/6/2022

1/26/2021

6/4/2019

6/21/2017

Type

Licensor

Client

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

News Snippet

Outcome Capital Announces Innara Health and Cardinal Health Partner to Advance Neonatal Development - Outcome Capital

Innara Health 's visibility and the pathway to the NTrainer System redesign gained momentum in 2020 after being selected to participate in the MedTech Innovator accelerator pediatric cohort .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Outcome Capital Team

7 Team Members

Outcome Capital has 7 team members, including current Founder, Managing Director, Oded Ben Joseph.

Name

Work History

Title

Status

Oded Ben Joseph

Oxford Bioscience Partners, Caliber Therapeutics, X-Cell Medical, Ester Neurosciences, and University of Michigan

Founder, Managing Director

Current

Jonathan Wallace

Founder

Current

Ellen S. Baron

Third500, Oxford Bioscience Partners, Human Genome Sciences, and Schering-Plough

Managing Director

Current

Arnie Freedman

Managing Director

Current

Paul Mieyal

Nephros, Wexford Capital, and Wechsler & Co.

Managing Director

Current

Name

Oded Ben Joseph

Jonathan Wallace

Ellen S. Baron

Arnie Freedman

Paul Mieyal

Work History

Oxford Bioscience Partners, Caliber Therapeutics, X-Cell Medical, Ester Neurosciences, and University of Michigan

Third500, Oxford Bioscience Partners, Human Genome Sciences, and Schering-Plough

Nephros, Wexford Capital, and Wechsler & Co.

Title

Founder, Managing Director

Founder

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.